BORA PHARMACEUTICALS LTD (6472) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of BORA PHARMACEUTICALS LTD stock TWD 639, price TWD 409, upside +56.2%, quality 50 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range 78.59 TWD – 2,585 TWD · fair‑value band 341.60 TWD – 1,156 TWD · the 409.00 TWD price screens below the 638.88 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow BORA PHARMACEUTICALS in your weekly email
Every Wednesday you see whether BORA PHARMACEUTICALS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs.
Show moreShow less
The company also offers contract development and manufacturing services and technical services for the development of pharmaceutical products.
In addition, it provides Western pharmaceuticals, including central nervous system medications, antibiotics, and gastrointestinal medications; and nutritional and vitamin supplements, physical recovery, and health care products.
The company sells its products directly to clinics, pharmacies, pharmacy chains, and drug stores, as well as through distributors to medical centers, corporate and public hospitals, and regional and district hospitals.
Bora Pharmaceuticals Co., LTD. was incorporated in 2007 and is based in Taipei City, Taiwan.
Stock analysis
BORA PHARMACEUTICALS LTD (6472) currently trades at 409.00 TWD, while our model-based Fair Value estimate is 638.88 TWD, implying the stock looks roughly 36% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 1,086 TWD per share, and 15 of the 26 models we run sit above the 409.00 TWD price.
Bear case: the Dividend Discount group reads lowest at 165.81 TWD, and 11 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 341.60 TWD (bear) to 1,156 TWD (bull), the price of 409.00 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
BORA PHARMACEUTICALS LTD reported revenue of 19.0B TWD in FY2025 versus 4.9B TWD in FY2021, a compound +40.4%/yr. Reported net income was 3.0B TWD in FY2025, compounding +41.2%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 54.7B TWD (≈ $1.7B) Small · P/E ratio 28.8 · P/S ratio 2.80 · EPS (TTM) 14.22 TWD · Dividend yield 2.4% · Net margin 7.9% · Return on equity 12.1% · Return on assets (EBIT) 11.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 56%, 6472 screens cheaper than that median.
Fair Value models
Bear341.60 TWDFair Value 638.88 TWDBull1,156 TWD
Price 409.00 TWD · Upside +56.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (4.22 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+57.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+65.9%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+41.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+39.4%
Dividend (yield on the price)2.4%
Per share before 2025divided by the spin-off factor 1.1998
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 17%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+21.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +9.5% a year for the price and +19.3% for the forecasts.
Compare BORA PHARMACEUTICALS LTD with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside+56.2% · Top 25%
Profitability
Return on equity (12 months)12.1% · Above median
Return on assets6.7% · Above median
Net margin (12 months)7.9% · Above median
Operating margin (12 months)16.8% · Above median
Growth and dividend
Revenue growth (quarter YoY)21.0% · Top 25%
Dividend yield (12 months)2.4% · Above median
Balance sheet
Debt / equity0.77× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)28.8× · Pricier than median
P/B3.55× · Priciest 25%
P/S (12 months)2.80× · Pricier than median
Price / free cash flow (fiscal year)16.5× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is BORA PHARMACEUTICALS LTD (6472) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 638.88 TWD versus a price of 409.00 TWD, about +56% upside (undervalued).
What is the fair value of 6472?
Our model-based fair value for BORA PHARMACEUTICALS LTD is 638.88 TWD (as of Nov 6, 2026), built from audited fundamentals. The current price: 409.00 TWD.
What is the quality score of 6472?
BORA PHARMACEUTICALS LTD has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BORA PHARMACEUTICALS LTD (6472)?
Our model-based price target is the fair value of 638.88 TWD (as of Nov 6, 2026) from 26 valuation models. Cautious scenario 341.60 TWD, optimistic scenario 1,156 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the BORA PHARMACEUTICALS LTD stock forecast for 2026?
Our models put fair value at 638.88 TWD, about +56% upside versus a price of 409.00 TWD (undervalued). Cautious scenario 341.60 TWD, optimistic scenario 1,156 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of BORA PHARMACEUTICALS LTD (6472)?
BORA PHARMACEUTICALS LTD reported trailing-twelve-month revenue of about 19.6B TWD (latest available figure, as of Nov 6, 2026).
Does BORA PHARMACEUTICALS LTD pay a dividend?
BORA PHARMACEUTICALS LTD currently shows a dividend yield of 2.44% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of BORA PHARMACEUTICALS LTD (6472) and when is the ex-dividend date?
BORA PHARMACEUTICALS LTD pays a dividend of 10.00 TWD per share a year, a dividend yield of 2.4%. The last ex-dividend date was Jul 31, 2026. A dividend has been paid every year since at least 2015. The payout ratio is 70.3% of earnings. Free cash flow covers the dividend 2.60 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into BORA PHARMACEUTICALS LTD (6472)?
For today's price to be fair in a discounted-cash-flow model, BORA PHARMACEUTICALS LTD would have to grow free cash flow by +11.2 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +60.2 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 6472 use?
Our models discount BORA PHARMACEUTICALS LTD at 10.3 %: a base by market capitalisation (small), damped by beta 0.44, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BORA PHARMACEUTICALS LTD that is +11.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has BORA PHARMACEUTICALS LTD (6472) delivered so far?
Over the past 5 years revenue at BORA PHARMACEUTICALS LTD grew +60.2 % a year. The price currently implies free-cash-flow growth of +11.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BORA PHARMACEUTICALS LTD (6472) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into BORA PHARMACEUTICALS LTD (+11.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BORA PHARMACEUTICALS LTD (6472)?
The free-cash-flow yield on the price is 6.06 %: that much free cash flow BORA PHARMACEUTICALS LTD produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BORA PHARMACEUTICALS LTD (6472)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BORA PHARMACEUTICALS LTD it is 638.88 TWD per share (as of Nov 6, 2026), against a price of 409.00 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is BORA PHARMACEUTICALS LTD stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 6472 trades below its calculated fair value: price 409.00 TWD, fair value 638.88 TWD, a gap of about +56% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6472?
No. The price is what the market pays today (409.00 TWD); the fair value is what the company's own numbers justify (638.88 TWD). For BORA PHARMACEUTICALS LTD the two are 229.88 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is BORA PHARMACEUTICALS LTD worth?
The market values BORA PHARMACEUTICALS LTD at about 54.7B TWD (market capitalisation, as of Nov 6, 2026). Per share that is 409.00 TWD; our models calculate a fair value of 638.88 TWD per share.
What do the bullish and bearish scenarios say about 6472?
Our models span a range for BORA PHARMACEUTICALS LTD: cautious scenario 341.60 TWD, base 638.88 TWD, optimistic 1,156 TWD per share (as of Nov 6, 2026, price 409.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6472?
BORA PHARMACEUTICALS LTD trades at a price-to-earnings ratio of 28.8 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 638.88 TWD is built from several models across several years. Other multiples: P/B 3.6, P/S 2.8, EV/EBITDA 15.4.
How solid is the balance sheet of BORA PHARMACEUTICALS LTD (6472)?
Balance-sheet figures for BORA PHARMACEUTICALS LTD (as of Nov 6, 2026): return on equity 12.1%, debt of 0.77 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 6472 from its 52-week high?
BORA PHARMACEUTICALS LTD trades at 409.00 TWD, about 34% below its 52-week high of 619.44 TWD and 25% above the low of 327.25 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 638.88 TWD is for.
Which stocks are comparable to BORA PHARMACEUTICALS LTD?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BORA PHARMACEUTICALS LTD stock attractive at the current price?
The data as of Nov 6, 2026: price 409.00 TWD, calculated fair value 638.88 TWD (+56%), Quality Score 50/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6472 calculated?
We run BORA PHARMACEUTICALS LTD through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 638.88 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BORA PHARMACEUTICALS LTD currently trades 36% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BORA PHARMACEUTICALS LTD (6472)?
The closing price on Nov 9, 2026 was 409.00 TWD. Our model-based fair value is 638.88 TWD, about +56% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BORA PHARMACEUTICALS LTD right now?
The model range is unusually wide (341.60 TWD to 1,156 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of BORA PHARMACEUTICALS LTD
How large is the market capitalisation of BORA PHARMACEUTICALS LTD (6472)?
The market capitalisation of BORA PHARMACEUTICALS LTD is 54.7B TWD (≈ $1.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BORA PHARMACEUTICALS LTD (6472)?
The price-to-sales ratio of BORA PHARMACEUTICALS LTD is 2.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BORA PHARMACEUTICALS LTD (6472)?
Earnings per share at BORA PHARMACEUTICALS LTD are 14.22 TWD (price ÷ EPS = P/E 28.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of BORA PHARMACEUTICALS LTD (6472)?
The dividend yield of BORA PHARMACEUTICALS LTD is 2.4% (payout 70.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of BORA PHARMACEUTICALS LTD (6472)?
The net margin of BORA PHARMACEUTICALS LTD is 7.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BORA PHARMACEUTICALS LTD (6472)?
The return on equity (ROE) of BORA PHARMACEUTICALS LTD is 12.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BORA PHARMACEUTICALS LTD (6472)?
On an EBIT basis the return on assets of BORA PHARMACEUTICALS LTD is 11.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BORA PHARMACEUTICALS LTD (6472)?
The operating margin of BORA PHARMACEUTICALS LTD is 16.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BORA PHARMACEUTICALS LTD (6472)?
Revenue at BORA PHARMACEUTICALS LTD is growing +21.0% versus a year earlier (3y avg +21.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BORA PHARMACEUTICALS LTD (6472)?
Earnings per share at BORA PHARMACEUTICALS LTD are growing −13.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does BORA PHARMACEUTICALS LTD (6472) carry?
The net debt of BORA PHARMACEUTICALS LTD is 13.1B TWD (fiscal year 2025, ≈ 4.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch BORA PHARMACEUTICALS LTD in the live analysis
One click puts BORA PHARMACEUTICALS LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026